Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lipocine (LPCN) Income from Continuing Operations (2016 - 2025)

Lipocine (LPCN) has disclosed Income from Continuing Operations for 13 consecutive years, with 3186832.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Income from Continuing Operations fell 43.63% year-over-year to 3186832.0, compared with a TTM value of 5475238.0 through Sep 2025, down 34.99%, and an annual FY2024 reading of 8352.0, up 100.05% over the prior year.
  • Income from Continuing Operations was 3186832.0 for Q3 2025 at Lipocine, down from 2205716.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 12624021.0 in Q4 2021 and bottomed at 6809041.0 in Q2 2021.
  • Average Income from Continuing Operations over 5 years is 1841799.26, with a median of 2631777.0 recorded in 2022.
  • The sharpest move saw Income from Continuing Operations soared 379.83% in 2021, then tumbled 176.07% in 2023.
  • Year by year, Income from Continuing Operations stood at 12624021.0 in 2021, then tumbled by 117.66% to 2229913.0 in 2022, then dropped by 2.35% to 2282253.0 in 2023, then soared by 178.09% to 1782183.0 in 2024, then plummeted by 278.82% to 3186832.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for LPCN at 3186832.0 in Q3 2025, 2205716.0 in Q2 2025, and 1864873.0 in Q1 2025.